Long-Term Results and Prognostic Factors in the Treatment of Achalasia with Botulinum Toxin

Background and Study Aims: Endoscopic therapy of achalasia by injection of botulinum toxin into the lower esophageal sphincter has very limited adverse effects and is initially successful in 70 % of patients. However, this result only lasts for 6 - 9 months on average in most patients and only half of them benefit for more than 1 year. The aim of this study was to find out which factors are predictive for a good long-term success.Patients and Methods: We retrospectively studied 25 patients with achalasia. The diagnosis had been proven by barium swallow and esophageal manometry. Therapy was carried out endoscopically between June 1996 and December 1998 by injection of 25 mouse units (MU) botulinum toxin into each of the four quadrants of the lower esophageal sphincter (LES). Lower esophageal sphincter pressure (LESP) was measured prior to and 1 week after endoscopic therapy. A standardized questionnaire was used for symptom assessment, at the initial presentation, at 1 week and at 2.5 ± 0.8 years after treatment.Results: The LESP was significantly reduced (pre-treatment 62.1 ± 15.2 mmHg vs. post-treatment 43.1 ± 12.5 mmHg; P < 0.01). Symptoms improved in 16 patients (pre-treatment symptom score 9.5 ± 2.9 vs. post-treatment symptom score 4.7 ± 1.8; P < 0.01). Nine patients showed no relevant improvement. From the 16 patients with a good initial response, two were lost to follow-up. In nine patients the outcome was still satisfactory after a mean of 2.5 years (1.5 - 4 years) (pre-treatment symptom score 9.5 ± 2.9 vs. symptom score at 2.5 years after Botox 5.1 ± 1.5; P < 0.05). These patients were on average 67.7 ± 12.5 years old. The remaining five patients received a second or third injection of botulinum toxin, but none improved substantially for more than 6 months. One of them eventually underwent pneumatic dilation, and three laparoscopic myotomy. Thus, botulinum toxin treatment was unsuccessful in 14 patients in all. These 14 patients were, on average, significantly younger than the nine successfully treated patients (46.1 ± 12.6 years vs. 67.7 ± 12.5 years; P < 0.01) and had significantly higher LESP values prior to botulinum toxin therapy (72.8 ± 8.9 mmHg vs. 47.8 ± 9.2 mmHg; P < 0.01).Conclusions: The long-term success of botulinum toxin injection into the LES in patients with achalasia is highest in elderly patients and in patients with an LESP not exceeding the upper normal level prior to treatment by 50 % or more. On the basis of our results, younger patients (< 55 years) with a severe increase in LESP do not seem to benefit from botulinum toxin injection and pneumatic dilation or myotomy may be more advantageous to them.

References

• 1 Panaccione R, Gregor J C, Reynolds R P. et al . Intrasphincteric botulinum toxin versus pneumatic dilatation for achalasia: a cost minimization analysis.  Gastrointest Endosc. 1999;  50 492-498
• 2 Wehrmann T, Kokabpick H, Jacobi V. et al . Long-term results of endoscopic injection of botulinum toxin in elderly achalasic patients with tortuous megaesophagus or epiphrenic diverticulum.  Endoscopy. 1999;  31 352-358
• 3 Kolbasnik J, Waterfall W E, Fachnie B. et al . Long-term efficacy of botulinum toxin in classical achalasia: a prospective study.  Am J Gastroenterol. 1999;  94 3434-3439
• 4 Annese V, Bassotti G, Coccia G. et al . A multicenter randomised study of intrasphincteric botulinum toxin in patients with oesophageal achalasia. GISMAD Achalasia Study Group.  Gut. 2000;  46 597-600
• 5 Annese V, Basciani M, Lombardi G. et al . Perendoscopic injection of botulinum toxin is effective in achalasia after failure of myotomy or pneumatic dilation.  Gastrointest Endosc. 1996;  44 461-465
• 6 Muehldorfer S M, Schneider T H, Hochberger J. et al . Esophageal achalasia: intrasphincteric injection of botulinum toxin A versus balloon dilation.  Endoscopy. 1999;  31 517-521
• 7 Pasricha P J, Ravich W J, Hendrix T R. et al . Intrasphincteric botulinum toxin for the treatment of achalasia.  N Engl J Med. 1995;  332 774-778
• 8 Pasricha P J, Rai R, Ravich W J. et al . Botulinum toxin for achalasia: long-term outcome and predictors of response.  Gastroenterology. 1996;  110 1410-1415
• 9 Thumshirn M, Fried M. Botulinum toxin: the overall cure for defective relaxation.  Endoscopy. 1999;  31 392-397
• 10 Vaezi M F, Richter J E, Wilcox C M. et al . Botulinum toxin versus pneumatic dilatation in the treatment of achalasia: a randomised trial.  Gut. 1999;  44 231-239
• 11 Prakash C, Freedland K E, Chan M F. et al . Botulinum toxin injections for achalasia symptoms can approximate the short term efficacy of a single pneumatic dilation: a survival analysis approach.  Am J Gastroenterol. 1999;  94 328-333
• 12 Stark G A, Castell D O, Richter J E. et al . Prospective randomized comparison of Brown-McHardy and microvasive balloon dilators in treatment of achalasia.  Am J Gastroenterol. 1990;  85 1322-1326
• 13 Patti M G, Feo C V, Arcerito N. et al . Effects of previous treatment on results of laparoscopic Heller myotomy for achalasia.  Dig Dis Sci. 1999;  44 2270-2276
• 14 Andrews C N, Anvari M, Dobranowski I. Laparoscopic Heller's myotomy or botulinum toxin injection for management of esophageal achalasia. Patient choice and treatment outcomes.  Surg Endosc. 1999;  13 742-746
• 15 Bonavina L, Incarbone R, Antoniazzi L. et al . Previous endoscopic treatment does not affect complication rate and outcome of laparoscopic Heller myotomy and anterior fundoplication for oesophageal achalasia.  Ital J Gastroenterol Hepatol. 1999;  31 827-830
• 16 Bonavina L, Incarbone R, Reitano M. et al . Does previous endoscopic treatment affect the outcome of laparoscopic Heller myotomy?.  Ann Chir. 2000;  125 45-49
• 17 Horgan S, Hudda K, Eubanks T. et al . Does botulinum toxin injection make esophagomyotomy a more difficult operation?.  Surg Endosc. 1999;  13 576-579
• 18 Schmitt T, Wehrmann T. Selective denervation with the botulinum toxin as a therapeutic principle in the gastrointestinal tract.  Dtsch Med Wschr. 1999;  124 197-203
• 19 Fishman V M, Parkman H P, Schiano T D. et al . Symptomatic improvement in achalasia after botulinum toxin injection of the lower esophageal sphincter.  Am J Gastroenterol. 1996;  91 1724-1730
• 20 Annese V, Basciani M, Perri F. et al . Controlled trial of botulinum toxin injection versus placebo and pneumatic dilation in achalasia.  Gastroenterology. 1996;  111 1418-1424